1. Longer testing interval may impact the outcome of a prostate biopsy following the index PSA test due to longer time for a potential tumour to grow from the pre-index PSA to the index PSA, or due to a symptomatically driven biopsy diagnosed during the longer interval between the index PSA and the next PSA test.
Longer testing interval may impact the outcome of a prostate biopsy following the index PSA test due to longer time for a potential tumour to grow from the pre-index PSA to the index PSA, or due to a symptomatically driven biopsy diagnosed during the longer interval between the index PSA and the next PSA test. This study takes both of these aspects of longer testing intervals into consideration by analysing1 prostate cancers diagnosed at a prostate biopsy following a testing PSA; and2 prostate cancers diagnosed symptomatically within the follow-up time of 1, 2, 3, 4 and 5–8 years of the index PSA of men who were tested annually, biennially, 3 yearly, 4 yearly or 5–8 yearly, respectively. PSA, prostate-specific antigen.
Thorgerdur Palsdottir et al. BMJ Open 2019;9:e027958
©2019 by British Medical Journal Publishing Group